Progress in science is often determined by the development of new methods. Chromosomal banding and painting have played a major part in revealing the cytogenetic changes that occur in human cancer (balanced and nonbalanced translocations, deletions, insertions, and inversions). The correct number of human chromosomes was not established until 1956, when tissue culture techniques allowed the human chromosome complement to be scored correctly (Tjio and Levan, 1956) . Techniques that seem commonplace now, such as stimulation of cultured lymphocytes with phytohemagglutinin (Nowell and Hungerford, 1960b) , led to major discoveries and the development of more refined techniques for chromosome analysis.
The Philadelphia chromosome in chronic myelogenous leukemia (CML), described by Nowell and Hungerford (1960a) , was the first example of a consistent aberrant autosomal chromosome in a human cancer. A further critical development that placed chromosomal aberrations as causative elements in tumorigenesis was the demonstration that the Philadelphia chromosome was a reciprocal chromosomal translocation involving chromosome 9 and chromosome 22, t(9;22) (q34;q11) (Rowley, 1973) . In the 1980s, the breakpoint of the Philadelphia chromosome was cloned to reveal the fusion of the BCR and ABL genes ( Figure 1A) , and the resulting fusion protein was shown to be oncogenic (Bartram et al., 1983; de Klein et al., 1982) . In 1992, gene fusions in solid tumors-thyroid tumors and sarcomas (Ewing's sarcoma and myxoid liposarcoma)-were discovered (reviewed in Rabbitts, 1994) . There are now many characterized recurrent gene fusions in human cancers (reviewed in Mitelman et al., 2007) . Genes involved in these fusions, such as MLL, EWS, and RET, may have many different fusion partners contributing to leukemia, sarcoma, or carcinoma, respectively (Rabbitts, 1994) ( Figure 1A) . Further, there are many oncogenes activated as a consequence of chromosomal translocations resulting in a new transcriptional environment principally in hematopoietic neoplasias where TCR (encoding the T cell receptor) or IG (encoding immunoglobulins) genes are involved ( Figure 1B ) (for example, see Aifantis et al., 2008) .
The Balance of Probability Favors Gene Fusions
The discovery of gene fusions was an outstanding development. In retrospect, it should have been expected in view of the exon/intron organization of genes and the modular structure of proteins, which corresponds (at least in part) to exon organization. Given the often large size of introns, it would be expected on a probabilistic basis that breaks within genes would occur within introns and that fusion genes would be the most likely outcome of chromosomal breakage and rejoining. Furthermore, active genes are more likely to be targets as the accessibility of chromatin (associated with active genes) is a key element in facilitating translocations/inversions and may even occur by corecruitment to the same transcription factories (Osborne et al., 2007) .
It is also predictable that nonrecurrent gene fusions will occur in tumors by chromosome breakage and rejoining within intronic regions (genetic instability). Nonrecurrent events may contribute to the development and maintenance of the individual tumor (idiopathic) (Rabbitts, 1994) or have no consequence at all. In some cases-as found in mouse modeling of chromosomal translocations using the Cre-loxP system (Forster et al., 2003) -it may be that nontumorigenic gene fusions occur that create fusions with exons in opposite transcriptional orientations. These may persist in the tumors that appear in patients.
There are parallels between the function of fusion gene products and the roles of the individual proteins in normal development (Rabbitts, 1991) . For example, genes required in differentiation pathways (e.g., the mixed lineage leukemia gene, MLL) may also be involved in gene fusions in acute neoplasias. The MLL protein is frequently found as part of a fusion protein in myeloid and lymphoid lineage tumors (Rowley, 2000) . MLL controls both primitive and definitive hematopoiesis (Armstrong et al., 2003) , behaving like a master gene in both normal and neoplastic settings. This property is found in many of the consistently fused genes in acute hematopoietic and mesenchymal malignancies (the translocation master gene hypothesis; Rabbitts, 1991) .
Gene Fusions in Carcinomas
Although cytogenetic analyses of carcinomas (that is, tumors of epithelial cell origin) have lagged behind those of
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Terence H. Rabbitts 1, * hematopoietic malignancies and sarcomas, it is now clear that carcinomas also have chromosomal abnormalities that result in the formation of fusion genes. The first example found in epithelial tumors, in the early 1990s, was in papillary thyroid carcinoma, the most prevalent form of thyroid cancer. This gene fusion involves joining of the RET gene encoding a tyrosine kinase receptor with the CCDC6 gene (previously D10S170); there are also nine other fusions involving the tyrosine kinase domain of RET in papillary thyroid carcinoma (Fusco et al., 1987; Grieco et al., 1988) (Tognon et al., 2002) . Transformation by the fusion protein ETV6-NTRK3 works through the RAS-MAPK and PI3K-AKT signaling pathways and activates the AP1 transcription complex . Recent studies have identified important new gene fusions in prostate and lung cancer. In prostate cancer, bioinformatics approaches assessing gene expression have revealed that ETS family transcription factor genes form fusion products in many prostate tumors. Initially, a gene encoding a transmembrane serine protease TMPRSS2 (an androgen-responsive gene; Tomlins et al., 2005) was found to be fused with ERG (ETS-Related Gene) by either inversion of chromosome 21 or by interstitial deletion of chromosome 21q22; a TMPRSS2-ETV1 gene fusion was found to be caused by chromosomal translocation between chromosomes 21 and 7. Additional ETS gene fusions have been described involving other androgenresponsive genes or ubiquitous promoters (Kumar-Sinha et al., 2008) ( Figure  1C ). The consequence of gene fusions in prostate cancer seems to involve one of two features: either androgen-responsive and ubiquitously expressed promoters control ETS gene expression, or 5′ untranslated regions are fused to the ETS gene so that the protein product is not a chimera (typical of hematopoietic or mesenchymal cancers), but rather is a deregulated ETS protein. In essence, this resembles the forced expression of oncogenes often found in lymphoid tumors ( Figure 1B) . After chromosomal translocation, expression of genes like (Rabbitts, 1994) . Gene fusions happen when breaks occur in introns, causing a new splicing combination that results in exon fusions, leading to protein fusion products. Forced expression of oncogenes through rearrangements in immunoglobulin (IG) or T cell receptor (TCR) genes is found in B cell neoplasias (e.g., MYC in Burkitt's lymphoma) and T cell neoplasias (e.g., LMO2 in T cell acute leukemia). Often, the transcriptional promoter of the oncogene accompanies the coding exons, causing aberrant expression of the mRNA but production of a normal protein. MYC mutations are the exception in translocations involving IG loci in Burkitt's lymphoma (Rabbitts et al., 1983) . (C) Gene fusions in lung and prostate cancer. Chromosomal translocations in lung cancer may involve kinase domain-encoding genes such as ALK and ROS (Rikova et al., 2007) . In prostate cancer, ETS gene family members are fused to androgen-responsive genes or ubiquitous promoters that sometimes contribute noncoding exons to fusions with ETS coding exons. BCL2 in follicular lymphoma or LMO2 in T cell acute leukemia results in a normal protein product but with aberrant control of transcription.
Recurrent gene fusions resulting in quintessential protein fusion products have also been found in lung cancer. Using a new approach-reminiscent of pioneering experiments identifying cellular transforming genes by transfection of tumor DNA into nontransformed fibroblasts (reviewed in Karnoub and Weinberg, 2008) -fusion between the anaplastic lymphoma kinase gene (ALK) and the echinoderm microtubule-associated protein-like 4 gene (EML4) has been detected in a subset of non-small cell lung cancers (NSCLCs) (Soda et al., 2007) (Figure 1C ). The EML4-ALK fusion gene is created by an inversion of chromosome 2p and encodes a fusion protein retaining the kinase domain of ALK. Further, ROS kinase (highly expressed in NSCLCs) also becomes part of a fusion protein in lung tumors, with the transmembrane portions of either SLC34A2 or CD74 (Rikova et al., 2007) creating the chimeric kinase. The importance of kinase signaling pathways and mutations in lung cancer has been clear from the prevalence of overexpressed or mutated RAS and PI3K in lung tumor tissue. This connection is now solidified with the identification of the ALK and ROS fusion proteins in lung tumors.
Different Biology, Different Fusion Protein Functions
Carcinomas encompass potentially invasive cancers that arise from the epithelium, which is the layer of cells lining cavities and surfaces (e.g., mouth, esophagus, lung, gut) or lining the ducts of glands (e.g., thyroid, breast, prostate). The developmental potential of stem cells in epithelial layers differs from that of blood or mesenchymal stem cells (Figure 2) , and so the types of genetic abnormality resulting in tumor formation are also likely to differ. Hematopoietic stem cells and mesenchymal stem cells undergo differentiation into diverse lineages ( Figures 2B and 2C ) that have distinct transcriptomes. These transcriptomes deliver the complex differentiation programs needed to produce diverse types of cell progeny. Conversely, epithelial stem cells undergo fewer differentiation steps and act to directly replenish layers of depleted cells at the epithelial surface.
In carcinomas, we see a trend toward oncogenic proteins that are involved in signaling pathways that activate cell proliferation or maintain homeostasis. Gross chromosomal mutations that affect signaling pathways may occur more frequently in locations, such as the airways, where there is contact with environmental agents or carcinogens. The gene fusions in lung tumors involving kinases (ALK and ROS) exemplify the link between the chromosomal abnormality, the gene fusion, the protein product, and abnormal signaling. The recent findings of mutations in the ALK gene in neuroendocrine tumors supports this pathway to tumorigenesis George et al., 2008; Janoueix-Lerosey et al., 2008; Mosse et al., 2008 ). An apparent exception is the association of gene fusions involving the ETS family of transcription factors with prostate cancer. The mechanism and role of inappropriate expression of these fusion proteins in prostate cancer has not been fully evaluated as yet. However, expression array analysis of prostate tumors carrying ETS gene abnormalities suggests that ETS proteins are involved in a broad range of normal and abnormal cellular processes from adhesion to invasion . Although fusion genes in carcinomas point to the importance of aberrant signaling cascades in the formation of these tumors, kinase involvement is not exclusive to carcinomas given that activated kinases such as BCR-ABL are the cause of chronic leukemia.
The Future
Since the Philadelphia chromosome was discovered and shown to be a reciprocal translocation, the importance of chromosomal abnormalities in defining molecular events that initiate and maintain tumors has been established for all forms of human cancer. Undoubtedly, further consistent reciprocal and nonreciprocal translocations, intrachromosomal deletions (possibly also insertions), and inversions (associated with DNA replication and repair events such as breakage and rejoining), followed by clonal selection, will be discovered. This will lead to the identification of new gene fusions (Rabbitts, 1994) . In addition, gene activation (as seen in lymphoid tumors) may also be discovered in carcinomas.
Application of new high-throughput genome sequencing technologies has begun to fulfill the promise of the facile and rapid discovery of new gene fusions (Campbell et al., 2008; Ley et al., 2008) . These technologies should reveal, in the complex genomes of all human malignancies, new recurrent abnormalities and nonrecurrent (idiopathic) oncogenic abnormalities that ensure development or maintenance of the individual tumor. They should also reveal abnormalities that have no oncogenic role (Rabbitts, 1994) ; these can be considered to be passenger abnormalities, akin to the passenger somatic mutations discovered by systematic sequencing of cancer genomes (Greenman et al., 2007; Wood et al., 2007) .
The importance of fusion proteins in cancer cannot be overstated, both for understanding more about the complex events underlying cancer and for identifying suitable therapeutic targets. However, a measure of caution is needed with respect to fusion proteins as therapeutic targets. Although the fusion proteins are tumor-specific targets, they are mostly intracellular molecules that are not expressed on the tumor cell surface. In addition, many are not enzymes but rather are involved in protein-protein or protein-nucleic acid interactions, making them more challenging drug targets. This contrasts with the ABL kinase of the BCR-ABL fusion protein, which is targeted by the drug Gleevec that binds competitively to the ATP-binding site of the kinase (Sawyers, 2005) .
Many gross chromosomal changes should prove valuable for early detection of cancer, leading to better informed clinical decisions. The recent finding of trans-spliced fusion mRNAs in normal endometrial stromal cells identical to those found in endometrial stromal tumors is an unexpected complication, and we clearly need to know more about how fusion mRNAs are created through trans-splicing. Molecular biologists have highlighted a plethora of gene fusions and their protein products, and it is now incumbent on us to turn these discoveries into new diagnostic and therapeutic regimens for combating cancer.
